Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Return on Sales (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Return on Sales for 5 consecutive years, with 0.83% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 21.0% to 0.83% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.04% through Dec 2025, up 97.0% year-over-year, with the annual reading at 1.04% for FY2025, 97.0% up from the prior year.
  • Return on Sales for Q4 2025 was 0.83% at Rhythm Pharmaceuticals, up from 1.03% in the prior quarter.
  • The five-year high for Return on Sales was 1250.0% in Q1 2021, with the low at 129.16% in Q2 2021.
  • Average Return on Sales over 5 years is 49.53%, with a median of 1.84% recorded in 2023.
  • Peak annual rise in Return on Sales hit 12421bps in 2022, while the deepest fall reached -128507bps in 2022.
  • Over 5 years, Return on Sales stood at 27.99% in 2021, then surged by 119bps to 5.28% in 2022, then tumbled by -133bps to 1.72% in 2023, then skyrocketed by 40bps to 1.04% in 2024, then grew by 20bps to 0.83% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 0.83%, 1.03%, and 0.96% for Q4 2025, Q3 2025, and Q2 2025 respectively.